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S U M M A R Y
Objectives: Data on prognostic factors among children with severe pneumonia are scarce in middle-
income countries. We investigated prognostic factors for an adverse outcome among children admitted
to the Hoˆpital d’Enfants de Rabat, Morocco with World Health Organization-deﬁned clinically severe
pneumonia (CSP).
Methods: Children aged 2–59 months admitted to the hospital and fulﬁlling the CSP deﬁnition were
recruited into this 13-month prospective study. A poor prognosis was deﬁned as death, a need for
intensive care, or a Respiratory Index of Severity in Children (RISC) score 3. Multivariate logistic
regression was performed to ascertain independent predictive factors for a poor prognosis.
Results: Of the 689 children included in this analysis, 55 (8.0%) required intensive care and 28 died
(4.0%). Five hundred and two (72.8%) children were classiﬁed as having a good prognosis and 187 (27.2%)
as having a poor prognosis. A history of prematurity (odds ratio (OR) 2.50, 95% conﬁdence interval (CI)
1.24–5.04), of fever (OR 2.25, 95% CI 1.32–3.83), living in a house with smokers (OR 1.79, 95% CI 1.18–
2.72), impaired consciousness (OR 10.96, 95% CI 2.88–41.73), cyanosis (OR 2.09, 95% CI 1.05–4.15), pallor
(OR 2.27, 95% CI 1.34–3.84), having rhonchi on auscultation (OR 2.45, 95% CI 1.58–3.79), and human
metapneumovirus infection (OR 2.13, 95% CI 1.13–4.02) were all independent risk factors for an adverse
outcome, whereas a history of asthma (OR 0.46, 95% CI 0.25–0.84) was the only independent risk factor
for a positive outcome.
Conclusions: The early identiﬁcation of factors associated with a poor prognosis could improve
management strategies and the likelihood of survival of Moroccan children with severe pneumonia.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/3.0/).
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license (http://creativecommons.org/licenses/by-nc-sa/3.0/).accounting for almost 1.4 million annual deaths, with around one
sixth of the deaths occurring in children under the age of ﬁve.1
Indeed, the death toll imposed by respiratory infections represents
a massive burden for the fragile health systems in the developing
world, where over 90% of all global deaths occur,2 and this cannot
be sufﬁciently emphasized. Respiratory infections cause a variety
of clinical syndromes, of which pneumonia – perhaps the most
paradigmatic and severe of all – is the most commonly associated
with an adverse outcome, causing over 90% of all deaths.3ciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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Streptococcus pneumoniae4 and Haemophilus inﬂuenzae type b
(Hib)5 being the two most frequent underlying aetiologies.
Respiratory viruses are typically the causes of upper and lower
respiratory infections with a more benign course, although
their pathogenic potential can sometimes be comparable to that
of bacteria or even worse; respiratory syncytial virus (RSV) is
one of the most common viruses involved in severe childhood
disease.6 Whatever the underlying cause, case-fatality rates
among under-ﬁves hospitalized with pneumonia are reported
to be around 19%.7
In the developing world, currently existing interventions to
reduce pneumonia-related morbidity and mortality include the
implementation of anti-pneumonia vaccines through the Expand-
ed Programme on Immunization during infancy,8 and the adequate
diagnosis and prompt treatment of clinical cases with antibiotics,
in accordance with the Integrated Management of Childhood
Illnesses (IMCI) algorithms,9 under the assumption that in such
settings the majority of severe pneumonia cases are of bacterial
origin.
Despite the increasing availability of preventive vaccines,
morbidity amongst those children who do become infected
remains high, possibly in relation to the many challenges faced
in the diagnosis and management in resource-constrained settings.
The early identiﬁcation of risk factors for a poor outcome among
pneumonia patients could help prioritize the management of those
patients with an uncertain prognosis and perhaps increase their
likelihood of surviving. Previous studies have described a series of
factors including young age of the patient (or the patient’s mother),
malnutrition, anaemia, or the conﬁrmation of grunting, cyanosis,
or chest indrawing, among others, as harbingers of a negative
outcome.10–13
Scarce and limited epidemiological, clinical, and microbio-
logical data are available regarding paediatric respiratory
tract infections in the Kingdom of Morocco, a middle-income
country in north-western Africa, although the World Health
Organization (WHO) estimates that up to 26.5% of all deaths in
children aged 1–59 months are secondary to pneumonia.14 In
this analysis, part of a wider surveillance project on the
aetiology of paediatric respiratory infections, we aimed to
describe factors associated with a poor outcome among
hospitalized children under the age of ﬁve admitted to a
Moroccan reference hospital with a diagnosis of WHO-deﬁned
severe pneumonia.
2. Materials and methods
2.1. Study setting and procedures for recruited children
This prospective study was conducted from November 2010 to
December 2011 at the Hoˆpital d’Enfants de Rabat (HER), in
Morocco’s capital. Children aged 2–59 months admitted to HER
with respiratory symptoms were identiﬁed and approached for
recruitment if they fulﬁlled the WHO deﬁnition of clinically severe
pneumonia (CSP),15,16 namely a history of cough or reported
breathing difﬁculty and increased respiratory rate (RR) according
to age,16 together with chest indrawing. After parents had signed
an informed consent form, recruited children underwent stan-
dardized procedures upon admission, including pulse oximetry
(Bionics PalmCare), an anteroposterior chest X-ray, nasal and
pharyngeal swabs for the diagnosis of bacterial infection/carriage,
and nasopharyngeal aspirates (NPA) for the diagnosis of respira-
tory viruses. A minimum of 2 ml venous blood was also collected
for blood culture, full blood cell count, and biochemical
determinations, including C-reactive protein (CRP) and procalci-
tonin (PCT).2.2. Deﬁnitions and clinical groups established
Admission and discharge diagnoses were coded using the
International Classiﬁcation of Diseases, 10th Revision (ICD-10).17
Hypoxemia implied an oxygen saturation (SaO2) <90%. Fever was
deﬁned as an axillary temperature of 37.5 8C. Nutritional status
was based on weight-for-age Z scores (WAZ), calculated using
the least mean square method and the 2000 Centers for Disease
Control and Prevention (CDC) growth reference.18 Invasive
bacterial disease implied the isolation of one or more non-
contaminant bacteria in blood or pleural ﬂuid.
For the purpose of this speciﬁc analysis, we deﬁned two
prognostic groups utilizing a composite deﬁnition based on
outcome (discharged alive vs. in-hospital death), requirement
for admission to the intensive care unit (ICU), and the Respiratory
Index of Severity in Children (RISC) score, a simple and validated
clinical score predicting the probability of death in children with
lower respiratory tract infections (LRTI), based on parameters
such as oxygen saturation, respiratory signs including indrawing
or wheezing, and nutritional status.19 Thus, we deﬁned a good
prognosis as a RISC score <3, no need for admission to the ICU, and
a discharge from hospital on the grounds of clinical improvement.
In contrast, a poor prognosis was deﬁned as the occurrence of
a death outcome, or an ICU admission, or a RISC score of 3.
2.3. Laboratory methods
The full laboratory methods of the general study from which
this analysis has been performed are detailed elsewhere.20 Blood
samples were cultured using an automated blood culture system
(BD Bactec; BD, New Jersey, USA), and bacterial isolates identiﬁed
by Phoenix Automated Microbiology System (PHX system; BD)
or colony morphology and biochemical tests. The detection of
S. pneumoniae and H. inﬂuenzae type B was also studied by
real-time PCR using a published in-house assay.21
The presence of DNA/RNA of inﬂuenza viruses A and B, RSV A
and B, parainﬂuenza viruses (PIV) 1, 2, 3, and 4, rhinovirus (RV),
adenovirus (ADV), enterovirus (EV), coronaviruses (CoV) 229E,
NL63, and OC43, human metapneumovirus (hMPV), Mycoplasma
pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis in
nasopharyngeal aspirates was also systematically investigated by
means of the TrueScience RespiFinder Pathogen Identiﬁcation
Panel (Applied Biosystems, New York, USA).
2.4. X-ray interpretation
Chest X-rays were interpreted independently by two paedia-
tricians following a WHO-designed X-ray interpretation proto-
col.22 Discordant results were resolved through a third reading.
Evidence of consolidation and/or pleural effusion was deﬁned as
‘endpoint pneumonia’. Other radiological endpoints included
interstitial inﬁltrates or normal radiographs.
2.5. Data management and statistical analysis
All study questionnaires were double-entered into a study
database using a program written in Filemaker Pro 12 (Filemaker
Inc., Santa Clara, CA, USA). Statistical analyses were done using
Stata 11 (StataCorp., College Station, TX, USA). Study variables
were counted and summarized in frequency tables. Means with
corresponding standard deviations (SD) or medians and inter-
quartile ranges are presented for normally and non-normally
distributed variables, respectively. Multivariate logistic regression
was performed with good prognosis/poor prognosis as the
outcome, using an automated backward and forward stepwise
estimation. Variables previously shown in the literature to
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were investigated. All variables that were associated with an
adverse outcome at a signiﬁcance level of p < 0.10 in the univariate
analysis were included in the initial model. The signiﬁcance
level for removal from the model was set at p = 0.06 and that for
addition to the model at p = 0.05. The strength of association was
determined by estimating the odds ratio (OR) and the 95%
conﬁdence intervals (CI).
2.6. Ethics
The protocol and informed consent documents were approved
by the Ethics Committee of the Hospital Clinic (Barcelona, Spain)
and by the Comite´ d’E´thique de la Recherche´ Biome´dicale (De´part
No. 1252–16De´c2009) of the Faculty of Medicine in Rabat.
3. Results
Out of almost 11 000 children seen in the emergency
department of HER during the 13-month study period, 700 under
the age of ﬁve were recruited into the study. Six hundred and
eighty-nine (98.4%) of these children had all the necessary
outcome data for inclusion in this speciﬁc risk factor analysis
(Figure 1). There were 28 deaths among these 689 patients (4.0%),
and 55 children (8.0%) required transfer to the ICU. The mean RISC
score for the overall study population was 1.36 (SD 1.34). With
regard to the two established risk groups, 502 (72.8%) children
were assigned to the good prognosis group and 187 (27.2%) to the
poor prognosis group (Figure 1).
The socio-demographic characteristics and health history
factors of the patients according to the prognosis group are shown
in Table 1. Patients with a worse outcome were signiﬁcantly
younger; no difference was found regarding gender. No signiﬁcant
differences were seen in terms of any seasonality of admission in
relation to outcome (data not shown). A history of having been
born prematurely, having received antibiotics preceding admis-
sion, or having an already known co-morbidity had a signiﬁcantFigure 1. Study ﬂowchart.association with a poorer outcome, while a history of previous
admission for LRTI or wheezing was strongly associated with a
good prognosis. Finally, being exposed to tobacco smoking at home
was also signiﬁcantly associated with a worse outcome.
In terms of the current admission history and other clinical
indicators, patients with a worse outcome were clearly more
severely ill on admission (including a signiﬁcantly higher mean
temperature, heart rate, and respiratory rate, and a lower oxygen
saturation) and had a signiﬁcantly longer history of symptoms
(Table 2). They were also signiﬁcantly more likely to have required
antibiotics during hospitalization (OR 8.75, p < 0.001). Their
nutritional status was also signiﬁcantly poorer, with up to 16.5%
(30/182) being severely malnourished. In terms of respiratory
signs, only wheezing was signiﬁcantly more common among
children with a good prognosis. Radiologically conﬁrmed pneu-
monia was again much more frequent (32.9% vs. 14.5%, p = 0.001)
amongst children with a poorer outcome, and hospitalizations
were signiﬁcantly more prolonged in this group (9.96 days vs.
4.31 days, p = 0.001).
Laboratory and microbiology ﬁndings also showed important
differences between the two groups, with children with a worse
outcome being signiﬁcantly more anaemic and more frequently
demonstrating elevated biomarkers of infection (PCT and CRP).
Importantly, no differences were seen according to the outcome
group in the mean white blood cell count or in the prevalence of
leukopenia or leukocytosis (Table 3). As expected, cases of
bacteraemia were signiﬁcantly more frequent among the group
with a poor outcome, and so were infections with hMPV. In
contrast, infections with RV appeared to be associated with a good
outcome (p = 0.001).
The multivariate analysis of factors associated with the
prognosis (Table 4) showed that a history of prematurity (OR
2.50, 95% CI 1.24–5.04), of fever (OR 2.25, 95% CI 1.32–3.83), living
in a house with smokers (OR 1.79, 95% CI 1.18–2.72), impaired
consciousness (OR 10.96, 95% CI 2.88–41.73), cyanosis (OR 2.09,
95% CI 1.05–4.15), pallor (OR 2.27, 95% CI 1.34–3.84), having
rhonchi on auscultation (OR 2.45, 95% CI 1.58–3.79), and hMPV
infection (OR 2.13, 95% CI 1.13–4.02) were all independent risk
factors for an adverse outcome, whereas a history of asthma (OR
0.46, 95% CI 0.25–0.84) was the only independent risk factor for
a positive outcome.
4. Discussion
The burden and impact of acute LRTIs in Morocco has not been
sufﬁciently addressed. The few available publications23–26 have
patchily presented data on speciﬁc microorganisms or generic
laboratory ﬁndings, but to our knowledge, this project has been the
ﬁrst to comprehensively describe the burden, aetiology, and
clinical characterization of severe paediatric pneumonia in a
tertiary referral Moroccan hospital.20 In this setting, paediatric
respiratory disease results in unacceptably high associated case-
fatality rates (28 deaths, giving a case-fatality rate (CFR) of 4.0%,
which is towards the upper bound of what has previously been
described for similar or even poorer settings, ranging from 0.8% to
4.8%7,27) and affects mostly infants.7 About a quarter of the
patients recruited into this study could be classiﬁed as having a
poor prognosis, and 8% of these patients required intensive care.
Importantly, the management of these patients seems to have
been adequately matched to the severity of their symptoms, with a
good availability of intensive care and a very high coverage of
oxygen and antibiotics, including broad-spectrum ones.20,28
Nosocomial infections, which in other settings may be an
important cause of in-hospital mortality, appear to have played
a moderate role in this series, as only about 14.2% of the patients
(4/28) had an admission duration longer than 10 days.
Table 1
Baseline socio-demographic characteristics of recruited patients, according to the prognosis groupa
Good prognosis (n = 502) Poor prognosis (n = 189) OR (95% CI) p-Value
Demographic characteristics
Age, months, mean  SD 23.40  14.80 16.00  12.10 0.001
Age <12 months 123 (24.50) 89 (47.59) 2.80 (1.97–2.98) 0.001
Female sex 187 (37.25) 62 (33.16) 0.84 (0.59–1.19) 0.32
Patient history
Prematurity 28 (5.59) 23 (12.30) 2.37 (1.33–4.33) 0.003
Breastfeeding 6 months 308 (61.72) 109 (58.30) 0.87 (0.62–1.22) 0.41
Vitamin A supplementation 461 (91.83) 168 (89.84) 0.79 (0.45–1.40) 0.67
Past morbidity and co-morbidity
Previous admission for ARI 182 (36.25) 39 (20.86) 0.46 (0.31–0.68) 0.001
History of wheezing or asthma 164 (32.67) 22 (11.76) 0.27 (0.17–0.44) 0.001
Antibiotic preceding admission 136 (27.09) 68 (36.36) 1.54 (1.08–2.20) 0.018
Existing co-morbidity 13 (2.60) 12 (6.50) 3.06 (1.37–6.83) 0.016
Vaccination history
Adequate vaccination status according to age 438 (87.43) 158 (84.95) 0.81 (0.50–1.31) 0.39
At least one dose of Hib vaccine 492 (98.01) 181 (96.80) 0.61 (0.22–1.70) 0.34
Proxy of socioeconomic level
Parents with high level of education 68 (13.55) 24 (12.83) 0.94 (0.57–1.55) 0.93
Medical insurance 137 (27.30) 40 (21.40) 0.72 (0.48–1.08) 0.28
Father’s occupation status 396 (79.68) 145 (79.23) 0.97 (0.64–1.47) 0.89
Mother’s occupation status 60 (11.98) 20 (10.70) 0.88 (0.51–1.50) 0.64
Family environment
Smoking exposure at home 192 (38.32) 87 (46.52) 1.04 (1–1.97) 0.05
Number of persons in the house >6 189 (37.65) 75 (40.11) 1.11 (0.80–1.57) 0.55
Rooms in the house >3 164 (32.67) 72 (38.50) 1.30 (0.91–1.83) 0.15
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; ARI, acute respiratory infection; Hib, Haemophilus inﬂuenzae type b.
a Results are n (%), unless stated otherwise.
I. Jroundi et al. / International Journal of Infectious Diseases 28 (2014) 164–170 167In this analysis, we aimed to identify patient risk factors (socio-
economic, clinical, and laboratory) upon arrival that could guide
the clinician’s response and help tailor the scarce resources
for improved patient management. Such factors, extensivelyTable 2
Clinical history, physical examination ﬁndings on admission, and outcome of recruited
Good progno
History of the current disease
Time interval between onset and admission (Days): mean  SD 3.40  4.29
History of fever 312 (62.28) 
History of cough 495 (98.80) 
History of runny nose 390 (77.84) 
History of vomiting 249 (49.70) 
History of diarrhoea 80 (15.97) 
Difﬁculties breastfeeding 141 (30.79) 
Impaired consciousness 3 (0.60) 
Symptoms and signs on admission
Malnourished (WAZ < 1 SD) 118 (23.89) 
WAZ > 1 SD 376 (76.11) 
WAZ < 1 to > 3 SD 111 (22.47) 
WAZ < 3 SD 7 (1.42) 
Axillary temperature, 8C, mean  SD 37.65  0.83
Hyperpyrexia (axillary temperature >39 8C) 50 (9.98) 
Respiratory rate, per min, mean  SD 58.68  12.5
Heart rate, per min, mean  SD 125.86  22.7
Oxygen saturation, %, mean  SD 95.37  3.12
WHO oxygen desaturation <90% 17 (3.53) 
Cyanosis 22 (4.38) 
Pallor 55 (11) 
Nasal ﬂaring 367 (73.11) 
Wheezing 416 (82.87) 
Crackles 40 (7.97) 
Rhonchi 215 (42.83) 
Radiologically conﬁrmed pneumonia 64 (14.48) 
Outcome
Received antibiotics during admission 139 (27.7) 
Length of admission (Days): mean  SD 5.24  4.31
RISC score, mean  SD 0.76  0.80
Transferred to ICU 0 (0) 
Died 0 (0) 
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; NA, Not applicable; WAZ, w
Severity in Children; ICU, intensive care unit.
a Results are n (%), unless stated otherwise.described in the pneumonia literature10–13,19,29–34 and currently
being speciﬁcally investigated as part of the PERCH (aetiology of
pneumonia) multisite case–control study,35 may change according
to the local or regional epidemiology of LRTI, warranting locally patients, according to the prognosis groupa
sis (n = 502) Poor prognosis (n = 189) OR (95% CI) p-Value
 5.56  7.85 NA 0.001
157 (83.96) 3.17 (2.06–4.87) 0.001
182 (97.85) 1.08 (1.04–1.13) 0.35
139 (74.33) 0.82 (0.56–1.21) 0.33
101 (54.01) 1.19 (0.85–1.67) 0.31
57 (30.48) 2.31 (1.56–3.42) 0.001
121 (67.22) 4.61 (3.19–6.67) 0.001
17 (9.09) 16.63 (4.81–57.45) 0.001
86 (47.25) 2.85 (1.99–4.07) 0.001
96 (52.75) 0.35 (0.24–0.5) 0.001
56 (30.77) 1.53 (1.05–2.24) 0.02
30 (16.48) 13.73 (5.91–31.89) 0.001
 38.07  0.88 NA 0.001
45 (24.32) 2.90 (1.84–4.56) 0.001
4 61.14  17.98 1.01 (1–1.02) 0.04
3 131.12  24.61 1.01 (1–1.02) 0.008
 93.31  6.35 NA 0.001
35 (19.44) 6.58 (3.50–12.38) 0.001
40 (21.40) 5.93 (3.34–10.52) 0.001
61 (32.62) 3.93 (2.56–6.04) 0.001
139 (74.33) 1.07 (0.73–1.57) 0.74
36 (19.22) 0.05 (0.02–0.08) 0.001
34 (18.18) 2.56 (1.56–4.22) 0.001
138 (73.80) 3.76 (2.55–5.53) 0.001
47 (32.87) 2.89 (1.84–4.52) 0.001
144 (77.0) 8.75 (5.64–13.57) 0.001
 7.09  9.96 NA 0.001
 2.98  1.14 NA 0.001
55 (29.41) NA 0.001
28 (14.97) NA 0.001
eight-for-age Z score; WHO, World Health Organization; RISC, Respiratory Index of
Table 3
Laboratory and microbiology ﬁndings for the patients recruited, according to the prognosis groupa
Good prognosis (n = 502) Poor prognosis (n = 189) OR (95% CI) p-Value
Biomarkers
High PCT levels (>5 ng/ml) 98 (20.04) 92 (49.73) 3.94 (2.69–5.77) 0.001
High CRP levels (>5 mg/dl) 100 (20.16) 60 (32.61) 1.91 (1.30–2.80) 0.004
Haemogram
WBC count, mean  SD 15.82  7.70 16.43  8.01 NA 0.42
Abnormal WBC (<5 or >20,  109/l) 84 (23.33) 38 (25.85) 1.15 (0.74–1.79) 0.54
Haemoglobin, g/l, mean  SD 11.62  2.82 10.56  1.87 NA 0.001
Anaemia <9 g/l 27 (7.44) 24 (16.11) 2.39 (1.32–4.32) 0.003
Biochemistry
Creatinine, Micromol/L, mean  SD 4.05  0.53 4.46  2.6 NA 0.34
Sodium, Micromol/L, mean  SD 135.73  3.9 136.72  6.47 NA 0.42
Potassium, Micromol/L, mean  SD 4.62  0.55 4.64  0.72 NA 0.88
Glycaemia, Micromol/L, mean  SD 95.97  40.61 114.5  63.61 NA 0.12
Bacteraemia 10 (2.03) 14 (7.50) 3.9 (1.68–9.01) 0.006
PCR results, microorganism isolated
Human metapneumovirus 33 (6.76) 27 (15.08) 2.48 (1.44–4.29) 0.007
Rhinovirus 282 (56.97) 72 (40.22) 0.50 (0.35–0.72) 0.001
Coronavirus 41 (8.28) 13 (7.26) 0.87 (0.45–1.66) 0.66
Bordetella pertussis 3 (0.61) 2 (1.12) 1.85 (0.31–11.16) 0.49
Mycoplasma 7 (1.41) 3 (1.68) 1.18 (0.30–4.61) 0.80
Inﬂuenza virus 14 (2.83) 10 (5.60) 2.03 (0.88–4.66) 0.08
Parainﬂuenza virus 92 (24.58) 44 (18.60) 1.43 (0.95–2.15) 0.08
Respiratory syncytial virus 93 (18.80) 32 (17.88) 0.94 (0.60–1.47) 0.78
Adenovirus 86 (17.37) 30 (16.76) 0.96 (0.61–1.51) 0.85
OR, odds ratio; CI, conﬁdence interval; SD, standard deviation; NA, Not applicable; PCT, procalcitonin; CRP, C-reactive protein; WBC, white blood cell count.
a Results are n (%), unless stated otherwise.
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have already described, impaired consciousness,10,13,33 cyanosis as
a proxy of hypoxemia,11–13,19,36 and pallor13,34,37 were three
clinical signs strongly and independently associated with a poor
prognosis, together with the presence of rhonchi. Wheezing,
normally associated with relatively benign LRTI (bronchitis and/or
bronchiolitis), and usually considered less frequent in developing
settings in comparison to rich countries,38 was very common in our
series (present in up to two-thirds of the patients) and highly
associated with viral infections,20 but carried a low associated CFR
and risk of a poor outcome. Although wheezing was not included in
the ﬁnal multivariate model because of being part of the composite
deﬁnition of the outcome (being part of the RISC score), we found
that a history of asthma was the only protective factor against a
negative outcome in our series.
Young age (infants <12 months vs. older children) was also
conﬁrmed as a risk factor for a poor prognosis, as has been
shown in other studies.11,19,32,33 This sets the rationale for
extra care when facing young infants with a respiratoryTable 4
Independent risk factors for a poor prognosis among admitted Moroccan children
with WHO-deﬁned severe pneumonia, according to multivariate analysisa
Risk factors for a poor prognosis Adjusted OR 95% CI p-Valueb
Lower Upper
History of prematurity 2.50 1.24 5.04 0.010
History of asthma 0.46 0.25 0.84 0.012
History of fever 2.25 1.32 3.83 0.003
Smoker at home 1.79 1.18 2.72 0.006
Pallor 2.27 1.34 3.84 0.002
Cyanosis 2.09 1.05 4.15 0.035
Rhonchi 2.45 1.58 3.79 <0.001
Impaired consciousness 10.96 2.88 41.73 <0.001
Human metapneumovirus infection 2.13 1.13 4.02 0.019
WHO, World Health Organization; OR, odds ratio; CI, conﬁdence interval.
a Other variables assessed in the model included having a chronic underlying
disease, fever on admission, hyperpyrexia, crackles, diarrhoea, high C-reactive
protein, high procalcitonin, bacteraemia, respiratory syncytial virus infection, and
rhinovirus infection.
b Likelihood ratio Chi-square test, 1 degree of freedom.symptomatology, likely warranting a more conservative approach
in terms of management.
Deﬁcient nutritional status or low birth weight has clearly been
established as a risk factor both for morbidity and mortality among
LRTI patients.10,19,30–33 In our series, a history of prematurity
(intrinsically linked with a low birth weight) was independently
associated with a high risk of dying. Similarly, under-nutrition,
although not included in the ﬁnal model because of being part of
the outcome deﬁnition of the RISC score, was also found to be
strongly associated with a higher likelihood of death, and was
highly prevalent, affecting about a quarter of the recruited patients
with a good outcome and almost half of those with a bad outcome.
In recent years, Morocco has made important efforts to introduce
programs for the prevention and management of childhood
diseases, including the promotion of exclusive breastfeeding,
supplementation of iron and vitamin A, and the introduction of
anti-pneumonia vaccines, all of which may have an impact on the
incidence of new malnutrition cases. However, malnutrition
prevalence rates remain high in Morocco,25,39 and unless
adequately addressed, will continue to negatively affect the
survival of patients with pneumonia.
Perhaps the most interesting ﬁnding in this analysis was the
adverse outcome associated with the speciﬁc pneumonia cases
secondary to hMPV. Among the 62 patients (9.1%) with this
infection, seven (11.3%) required ICU admission, three died, and
the mean RISC score was 1.84. The impact and real burden of this
relatively newly described human virus needs to be investigated
further,40–42 but our data clearly show its pathogenicity potential
and suggest that active surveillance for this virus should be
maintained in Morocco.
Our study also conﬁrmed the previously well-documented
association of smoking in the household and an adverse
outcome.43,44 However, we were not able to conﬁrm the
association of certain well-known risk factors with a higher risk
of death.10–13 Indeed, parental education, lack of breastfeeding,
vaccination status, unavailability of adequate medical care, co-
morbidities and co-infections, metabolic acidosis, and other
laboratory ﬁndings (leukocytosis, abnormal biomarkers, etc.),
although assessed for some or the majority of outpatients, could
I. Jroundi et al. / International Journal of Infectious Diseases 28 (2014) 164–170 169not be independently related to a poorer outcome, even though the
study sample size was relatively large and the univariate
association was evident. This does not limit the strength of our
results, but, in our opinion, may express that in this setting their
validity as prognostic markers appears less critical than in other
settings. Our study suffers from further limitations, including the
fact that it was conducted in an urban referral tertiary hospital
with good accessibility to intensive care, a factor that may have
inﬂuenced the outcome for some of these patients, thus under-
estimating the real impact that pneumonia may have in other less
advantaged or more rural areas of the country.
In conclusion, the wide implementation of anti-pneumococcal
and Hib vaccines and other known preventive measures will
certainly result in a signiﬁcant decrease in pneumonia-related
morbidity and mortality globally. However, in regions where
pneumonia remains a major cause of disease and death,
the emphasis on early identiﬁcation of risk factors known to be
globally or locally associated with a poor outcome and the
establishment of adequate case management strategies can
make an enormous difference in the prognosis of these patients.
In this respect, this study represents an important addition to the
signiﬁcant knowledge gaps related to paediatric pneumonia in
Morocco, and more widely in the Maghreb area, and provides
good evidence for new approaches to prevent and better manage
this deadly disease.
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